natgillin/translations-raw huggingface dataset:
Toksisk epidermal nekrolyse, angioødem, Stevens-Johnsons syndrom, erythema multiforme, eksfoliativ dermatit 
Rare toxic epidermal necrolysis, angioedema, Stevens-Johnson syndrome, erythema multiforme, exfoliative dermatitis
Ryst godt og overfør blandingen til beholderen med infusionsvæske. 
Shake well and transfer the resulting mixture to the infusion solution container.
Disse patienter bør ikke behandles med TIENAM med mindre hæmodialyse institueres inden for 48 timer. 
These patients should not receive TIENAM unless haemodialysis is instituted within 48 hours.
Samtidig administration af TIENAM og probenecid medførte minimale stigninger i imipenems plasmakoncentration og plasmahalveringstid. 
Concomitant administration of TIENAM and probenecid resulted in minimal increases in the plasma levels and plasma half-life of imipenem.
Hvis De har glemt at få TIENAM 
If you forget to use TIENAM
Stigning i serumaminotransferaser, stigning i serum alkalisk fosfatase 
Common increases in serum transaminases, increases in serum alkaline phosphatase
Der er set CNS-bivirkninger i form af myoklonier, konfusion eller krampeanfald, især når de anbefalede doser, baseret på nyrefunktion og legemsvægt, blev overskredet. 
CNS adverse reactions such as myoclonic activity, confusional states, or seizures have been reported, especially when recommended doses based on renal function and body weight were exceeded.
Dette præparat er kemisk uforligeligt med lactat og bør ikke blandes med opløsningsvæsker, der indeholder lactat. 
This medicinal product is chemically incompatible with lactate and should not be reconstituted in diluents containing lactate.
• Overfølsomhed over for andre carbapenem-antibiotka 
• Hypersensitivity to any other carbapenem antibacterial agent
Hvis De holder op med at få TIENAM 
If you stop using TIENAM
TIENAM 500 mg/500 indeholder 37,6 mg natrium (1,6 meq), hvilket bør tages i betragtning ved behandling af patienter på kontrolleret natriumdiæt. 
TIENAM 500 mg/500 mg contains 37.6 mg of sodium (1.6 mEq) which should be taken into consideration by patients on a controlled sodium diet.
Fortæl også Deres læge hvis De tager valproinsyre eller natriumvalproat (der bruges til behandling af epilepsi, manio-depressiv sygdom (bipolar lidelse), migræne eller skizofreni) eller blodfortyndende medicin som f.eks. warfarin. 
Also, tell your doctor if you are taking valproic acid or sodium valproate (used to treat epilepsy, bipolar disorder, migraine, or schizophrenia) or any blood thinners such as warfarin.
• Snurrende bevægelsesfornemmelse (vertigo), hovedpine 
• A spinning sensation (vertigo), headache
TIENAM kan anvendes til behandling af neutropene patienter med feber, der mistænkes for at være forårsaget af en bakteriel infektion. 
TIENAM may be used in the management of neutropenic patients with fever that is suspected to be due to a bacterial infection.
• Misfarvning af tænder og/eller tunge 
• Staining of the teeth and/or tongue
Pædiatrisk population med nyreinsufficiens 
Paediatric population with renal impairment
TIENAM er indiceret til behandling af følgende infektioner hos voksne og børn ≥ 1 år (se pkt. 
TIENAM is indicated for the treatment of the following infections in adults and children 1 year of age and above (see sections 4.4 and 5.1):
• Hudafskalning (toksisk epidermal nekrolyse) 
• Skin peeling (toxic epidermal necrolysis)
• Unormal leverfunktion påvist via blodprøver 
• Abnormal liver function detected by blood tests
Cilastatin er en specifik hæmmer af dehydropeptidase-I-enzymet og hæmmer effektivt metaboliseringen af imipenem, således at samtidig administration af imipenem og cilastatin resulterer i, at en terapeutisk antibakteriel koncentration af imipenem kan opnås i både urin og plasma. 
Cilastatin is a specific inhibitor of dehydropeptidase-I enzyme and effectively inhibits metabolism of imipenem so that concomitant administration of imipenem and cilastatin allows therapeutic antibacterial levels of imipenem to be attained in both urine and plasma.
• komplicerede intra-abdominale infektioner 
• complicated intra-abdominal infections
Før behandling med TIENAM initieres, skal patienterne udspørges grundigt med hensyn til forudgående overfølsomhedsreaktioner over for carbapenemer, penicilliner, cefalosporiner, andre beta-lactam-lægemidler og andre allergener (se pkt. 
Before initiating therapy with TIENAM, careful inquiry should be made concerning previous hypersensitivity reactions to carbapenems, penicillins, cephalosporins, other beta-lactams and other allergens (see section 4.3).
Derfor er nøje overholdelse af det anbefalede doseringsskema vigtig, specielt hos disse patienter (se pkt. 
Hence close adherence to recommended dose schedules is urged especially in these patients (see section 4.2).
En dosis på ≤500 mg/500 mg skal gives ved intravenøs infusion over 20 - 30 minutter. 
Each dose of 500 mg/500 mg should be given by intravenous infusion over 20 to 30 minutes.
• Infektioner der angriber lungerne (lungebetændelse) 
• Infection affecting the lungs (pneumonia)
Der er dog bivirkninger (som hallucinationer, svimmelhed, døsighed og vertigo) forbundet med dette præparat, som kan påvirke nogle patienters evne til at føre motorkøretøj eller betjene maskiner (se pkt. 
However, there are some side effects (such as hallucination, dizziness, somnolence, and vertigo) associated with this product that may affect some patients' ability to drive or operate machinery (see section 4.8).
Det anbefales, at infektioner, der mistænkes at skyldes, eller som bevisligt skyldes mindre følsomme bakterier (såsom Pseudomonas aeruginosa) samt meget svære infektioner (f.eks. hos neutropene patienter med feber) behandles med 25/25 mg/kg hver 6. time. 
It is recommended that infections suspected or proven to be due to less susceptible bacterial species (such as Pseudomonas aeruginosa) and very severe infections (e.g. in neutropenic patients with a fever) should be treated with 25/25 mg/kg administered every 6 hours.
Lægemidlet findes i pakninger med 1 hætteglas, 10 hætteglas og 25 hætteglas. 
The medicinal product is supplied in packs of 1 vial, 10 vials and 25 vials.
Samtidig administration af TIENAM og probenecid fordoblede plasmakoncentrationen og halveringstiden af cilastatin men havde ingen indflydelse på genfindingen af cilastatin i urinen. 
Concomitant administration of TIENAM and probenecid doubled the plasma level and half-life of cilastatin, but had no effect on urine recovery of cilastatin.
• Ændret mængde urin, urinmisfarvning 
• Changes in the amount of urine, changes in urine colour
Derefter sås ingen yderligere urinudskillelse af cilastatin. 
No further cilastatin appeared in the urine thereafter.
YDERLIGERE OPLYSNINGER TIENAM indeholder: Aktive stoffer: Imipenem og cilastatin. 
What TIENAM contains - The active substances are imipenem and cilastatin.
• Brystgener, vejrtrækningsproblemer, unormalt hurtig eller overfladisk vejrtrækning, smerte i øvre del af rygraden 
• Chest discomfort, difficulty breathing, abnormally fast and superficial breathing, pain in the upper spine
Hvis De er bekymret for, om De mangler at få en dosis, skal De kontakte en læge eller anden sundhedspersonale med det samme. 
If you are concerned that you may have missed a dose, contact your doctor or another healthcare professional immediately.
Rekonstituering: 
Reconstitution:
Patienterne bør have TIENAM efter hæmodialysen og med 12 timers interval, regnet fra afslutning af hæmodialysen. 
The patient should receive TIENAM after haemodialysis and at 12 hour intervals timed from the end of that haemodialysis session.
De symptomer på overdosering, som kan forekomme, svarer til bivirkningsprofilen; disse kan være krampeanfald, konfusion, tremor, kvalme, opkastning, hypotension, bradykardi. 
Symptoms of overdose that can occur are consistent with the adverse reaction profile; these may include seizures, confusion, tremors, nausea, vomiting, hypotension, bradycardia.
Multipel dosering havde ingen indflydelse på farmakokinetikken af hverken imipenem eller cilastatin, og der sås ingen akkumulation af imipenem/cilastatin (se pkt. 
Multiple dosing has no effect on the pharmacokinetics of either imipenem or cilastatin, and no accumulation of imipenem/cilastatin was observed (see section 4.2).
Imipenems farmakokinetik hos patienter med nedsat leverfunktion er ikke fastlagt. 
The pharmacokinetics of imipenem in patients with hepatic insufficiency have not been established.
Den sædvanlige dosis til børn i alderen 1 år eller ældre er 15/15 eller 25/25 mg/kg/dosis hver 6. time. 
The usual dose for children one year of age or older is 15/15 or 25/25 mg/kg/dose every 6 hours.
6.2, 6.3 og 6.6) før administration. 
TIENAM is to be reconstituted and further diluted (see section 6.2, 6.3 and 6.6) prior to administration.
Der er set nedsat valproinsyrekoncentration, som kan falde til under det terapeutiske område, når valproinsyre blev givet sammen med carbapenem. 
Decreases in valproic acid levels that may fall below the therapeutic range have been reported when valproic acid was co-administered with carbapenem agents.
Der er nogle bivirkninger forbundet med dette præparat (såsom hallucinationer (se, høre eller føle ting som i virkeligheden ikke er der), svimmelhed, søvnløshed og en snurrende bevægelsesfornemmelse), som kan påvirke nogle patienters evne til at køre bil eller motorcykel eller betjene maskiner (se pkt. 
There are some side effects associated with this product (such as seeing, hearing, or feeling something that is not there, dizziness, sleepiness, and a spinning sensation) that may affect some patients' ability to drive or operate machinery (see section 4).
Når der blev givet doser af imipenem-cilastatinnatrium (ca. 100/100 mg/kg/dag eller ca. 3 gange så meget som den sædvanligt anbefalede humane intravenøse dosis) til gravide cynomolgus-aber med en infusionshastighed, som svarer til klinisk brug hos mennesker, påvistes minimal maternal intolerance (lejlighedsvis opkastning), ingen dødsfald under graviditet, ingen tegn på teratogenicitet, men flere tilfælde af tidlig spontan abort i forhold til kontrolgrupperne (se pkt. 
When doses of imipenem-cilastatin sodium (approximately 100/100 mg/kg/day or approximately 3 times the usual recommended daily human intravenous dose) were administered to pregnant cynomolgus monkeys at an intravenous infusion rate which mimics human clinical use, there was minimal maternal intolerance (occasional emesis), no maternal deaths, no evidence of teratogenicity, but an increase in embryonic loss relative to control groups (see section 4.6).
Orale antikoagulantia 
Oral anti-coagulants
LISTE OVER HJÆLPESTOFFER Natriumhydrogencarbonat (E500) 
LIST OF EXCIPIENTS Sodium bicarbonate (E500)
• Betændelsestilstand i mave eller tarm (gastro-enteritis) 
• Inflammation of stomach or intestine (gastro-enteritis)
• Streptococcus A, B, C, G: Beta-lactam-følsomheden over for beta-hæmolytiske streptokokker gruppe A, B, C og G er udledt fra penicillinfølsomheden. 
• Streptococcus A, B, C, G: The beta-lactam susceptibility of beta-haemolytic streptococcus groups A,
Imipenems plasmahalveringstid var l time. 
The plasma half-life of imipenem was one hour.
TIENAM bør kun anvendes under graviditet, hvis den potentielle fordel kan retfærdiggøre den potentielle risiko for fostret. 
TIENAM should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus.
25 hætteglas 
25 vials
Patienter med kreatinin-clearance 5 ml/min./1,73 m2 bør ikke få TIENAM, medmindre hæmodialyse institueres inden for 48 timer. 
Patients with creatinine clearances of 5 ml/min/1.73 m2 should not receive TIENAM unless haemodialysis is instituted within 48 hours.
Det anbefales, at infektioner der mistænkes at skyldes, eller som bevisligt skyldes mindre følsomme bakteriestammer (såsom Pseudomonas aeruginosa) samt meget svære infektioner (f.eks. hos neutropene patienter med feber) behandles med 1.000 mg/1.000 mg hver 6. time. 
It is recommended that infections suspected or proven to be due to less susceptible bacterial species (such as Pseudomonas aeruginosa) and very severe infections (e.g. in neutropenic patients with a fever) should be treated with 1000 mg/1000 mg administered every 6 hours.
Stigning i serumaminotransferaser og basisk fosfatase er også hyppigt set. 
Increases in serum transaminases and in alkaline phosphatase are also commonly reported.
Ikke almindelig Positiv direkte Coombs test, forlænget protrombintid, fald i hæmaglobin, stigning i serumbilirubin, forhøjet serumkreatinin, forhøjet blod-ureanitrogen 
A positive direct Coombs' test, prolonged prothrombin time, decreased haemoglobin, increases in serum bilirubin, elevations in serum creatinine, elevations in blood urea nitrogen
Symptomer på overdosering kan omfatte krampeanfald, forvirring, rysten, kvalme, opkastning, lavt blodtryk og langsom hjerterytme (puls). 
Symptoms of overdose may include seizures, confusion, tremors, nausea, vomiting, low blood pressure and slow heart rate.
Koncentrationen af imipenem i urinen oversteg 10 g/ml i op til 8 timer efter indgift af en TIENAM-dosis på 500 mg/500 mg. 
Urine concentrations of imipenem exceeded 10 g/ml for up to eight hours after a 500 mg/500 mg dose of TIENAM.
Antikonvulsiv behandling skal fortsætte hos patienter med krampelidelse. 
Anticonvulsant therapy should be continued in patients with a known seizure disorder.
Dyreforsøg har vist, at toksiciteten af imipenem indgivet alene var begrænset til nyrerne. 
Animal studies showed that the toxicity produced by imipenem, as a single entity, was limited to the kidney.
I kliniske studier med 1.723 patienter, der blev behandlet med intravenøs imipenem/cilastatin, var de hyppigst rapporterede systemiske bivirkninger, der i det mindste var muligt relateret til behandlingen: kvlame (2,0%), diarré (1,8%), opkastning (1,5%), udslæt (0,9%), feber (0,5%), hypotension (0,4%), krampeanfald (0,4%) (se pkt. 
In clinical trials including 1,723 patients treated with imipenem/cilastatin intravenous the most frequently reported systemic adverse reactions that were reported at least possibly related to therapy were nausea (2.0%), diarrhoea (1.8%), vomiting (1.5%), rash (0.9%), fever (0.5%), hypotension (0.4%), seizures (0.4%) (see section 4.4), dizziness (0.3%), pruritus (0.3%), urticaria (0.2%), somnolence (0.2%).
Centralnervesystemet 
Central nervous system
Gram-positive aerober: 
Gram-negative aerobes:
Den rekonstituerede opløsning må ikke nedfryses. 
Do not freeze the reconstituted solution.
Grækenland: Primaxin 
Greece: Primaxin
Efter en enkelt intravenøs dosis TIENAM på 250 mg/250 mg indgivet 24 timer efter hæmodialyse var AUC for imipenem og cilastatin henholdsvis 3,7 gange og 16,4 gange højere sammenlignet med forsøgspersoner med normal nyrefunktion. 
Following a single 250 mg/250 mg intravenous dose of TIENAM given 24 hours after haemodialysis, AUCs for imipenem and cilastatin were 3.7-fold and 16.4-fold higher, respectively, as compared to subjects with normal renal function.
Ved indgift alene metaboliseres imipenem i nyrerne af dehydropeptidase-I. 5-40% genfandtes i urinen med et gennemsnit på 15-20 % i flere studier. 
Individual urinary recoveries ranged from 5 to 40%, with an average recovery of 15-20% in several studies.
* Yderligere proportional dosisreduktion skal foretages hos patienter med legemsvægt <70 kg. 
* A further proportionate reduction in dose administered must be made for patients with a body weight
Deres læge vil derfor vurdere, om De kan bruge TIENAM, mens De ammer. 
Therefore, your doctor will decide whether you should use TIENAM while breast-feeding.
Antibiotika-associeret kolit og pseudomembranøs kolit er set ved behandling med imipinem/cilastatin og med stort set alle andre antibiotika og kan i sværhedsgrad variere fra let til livstruende. 
Antibiotic-associated colitis and pseudomembranous colitis have been reported with imipenem/cilastatin and with nearly all other anti-bacterial agents and may range from mild to life-threatening in severity.
Samtidig anvendelse af et hensigtsmæssigt lægemiddel mod methicillin-resistente Staphylococcus aureas (MRSA) kan være indiceret, når MRSA-infektioner er mistænkt for eller påvist at være involveret i de godkendte indikationer. 
Concomitant use of an appropriate anti-MRSA agent may be indicated when MRSA infections are suspected or proven to be involved in the approved indications.
TIENAM bør ikke gives til børn under 1 år eller børn med nyreproblemer. 
Children TIENAM is not recommended in children less than one year of age or children with kidney problems.
Hos raske, ældre frivillige forsøgspersoner (65 - 75 år med normal nyrefunktion i forhold til alderen) svarede farmakokinetikken af en enkelt dosis TIENAM 500 mg/500 mg efter intravenøs administration over 20 minutter til den farmakokinetik, der kunne forventes hos forsøgspersoner med let nedsat nyrefunktion, hvor dosisjustering ikke ansås for at være nødvendig. 
In healthy elderly volunteers (65 to 75 years of age with normal renal function for their age), the pharmacokinetics of a single dose of TIENAM 500 mg/500 mg administered intravenously over 20 minutes were consistent with those expected in subjects with slight renal impairment for which no dose alteration is considered necessary.
Patienter med kreatinin-clearance 5 ml/min/1,73 m2 
Patients with a creatinine clearance of ≤5 ml/min/1.73 m2
• Betændelse i tyktarmen med alvorlig diarré 
• Inflammation of the colon with severe diarrhoea
Både imipenem og cilastatin fjernes fra cirkulationen ved hæmodialyse. 
Both imipenem and cilastatin are cleared from the circulation during haemodialysis.
• Alvorligt nedsat leverfunktion pga. betændelsestilstand (fulminant hepatitis) 
• Severe loss of liver function due to inflammation (fulminant hepatitis)
Til patienter med normal nyrefunktion (kreatinin-clearance >70 ml/min/1,73 m2) anbefales følgende dosisregime: 
For patients with normal renal function (creatinine clearance of >70 ml/min/1.73 m2), the recommended dose regimens are:
Det er vigtigt, at De fortæller Deres læge, hvis De ammer eller forventer at amme før De bruger TIENAM. 
It is important that you tell your doctor if you are breast-feeding or if you intend to breast-feed before receiving TIENAM.
Staphylococcus aureus (methicillin-følsom)* Staphylococcus koagulasenegative (methicillin-følsom) Streptococcus agalactiae 
Staphylococcus coagulase negative (Methicillin-susceptible) Streptococcus agalactiae
Pruritus vulvae 
Very rare pruritus vulvae
Et hætteglas indeholder natriumhydrogenkarbonat svarende til ca. 1,6 mEq natrium (ca. 37,6 mg). 
Each vial contains sodium bicarbonate equivalent to approximately 1.6 mEq of sodium (approximately 37.6 mg).
Dette er hyppigst set hos patienter med lidelser i centralnervesystemet (f. eks. hjernelæsioner eller krampeanfald i anamnesen) og/eller hos patienter med nedsat nyrefunktion, hvor akkumulering af de indgivne lægemidler kan opstå. 
These experiences have been reported most commonly in patients with CNS disorders (e.g. brain lesions or history of seizures) and/or compromised renal function in whom accumulation of the administered entities could occur.
Cyanose, takykardi, palpitationer 
Very rare cyanosis, tachycardia, palpitations
En dosis på >500 mg/500 mg skal indgives over 40 - 60 minutter. 
Each dose >500 mg/500 mg should be infused over 40 to 60 minutes.
Misfarvning af tænder og/eller tunge 
Rare staining of teeth and/or tongue
** Når TIENAM 500 mg/500 mg gives til patienter med kreatinin-clearance på 6 til 20 ml/min/1,73 m2 
** When the 500 mg/500 mg dose is used in patients with creatinine clearances of 6 to 20 ml/min/l.73 m2,
TIENAM må ikke anvendes under graviditet, medmindre Deres læge vurderer at den forventede fordel opvejer den mulige risiko for fostret. 
TIENAM should not be used during pregnancy unless your doctor decides the potential benefit justifies the potential risk to the foetus.
TIENAM kan bruges til behandling af patienter med nedsat antal hvide blodceller (neutropeni) med feber, der mistænkes for at skyldes en bakteriel infektion. 
TIENAM may be used in the management of patients with low white blood cell counts, who have fever that is suspected to be due to a bacterial infection.
Dosisjustering er ikke nødvendig (se pkt. 
There is no dose adjustment necessary (see section
I lighed med andre beta-lactam-antibiotika har den tid, hvor imipenemkoncentrationn overstiger MIC (T>MIC), vist sig at korrelere bedst med virkningen. 
Pharmacokinetic/Pharmacodynamic (PK/PD) relationship Similar to other beta-lactam antibacterial agents, the time that imipenem concentrations exceed the MIC (T>MIC) has been shown to best correlate with efficacy.
Det skal De vide, før De begynder at bruge TIENAM Sådan skal De bruge TIENAM Bivirkninger 
What TIENAM is and what it is used for Before you use TIENAM How to use TIENAM Possible side effects
• Unormal nyre-, lever- og blodfunktion påvist via blodprøver 
• Abnormal kidney, liver and blood function detected by blood tests
Ved behandling af patienter med kreatinin-clearance 5 ml/min/1,73 m2, som er i dialyse, bør dosisforskrifterne for patienter med kreatinin-clearance 6-20 ml/min/1,73 m2 anvendes (se tabel 1). 
When treating patients with creatinine clearances of 5 ml/min/1.73 m2 who are undergoing dialysis use the dose recommendation for patients with creatinine clearances of 6 to 20 ml/min/1.73 m2 (see table 1).
Agranulocytose 
Rare agranulocytosis
Øvrige: Chlamydia spp. 
Others: Chlamydia spp.
Efter en enkelt intravenøs dosis TIENAM på 250 mg/250 mg steg arealet under kurven (AUC) for imipenem 1,1 gange, 1,9 gange og 2,7 gange hos forsøgspersoner med henholdsvis let (kreatinin-clearance 50-80 ml/min/1,73 m2), moderat (kreatinin-clearance 30-<50 ml/min/1,73 m2) og svært (kreatininclearance <30 ml/min/1,73 m2) nedsat nyrefunktion, sammenlignet med forsøgspersoner med normal nyrefunktion (kreatinin-clearance >80 ml/min/1,73 m2). 
Following a single 250 mg/250 mg intravenous dose of TIENAM, the area under the curve (AUCs) for imipenem increased 1.1-fold, 1.9-fold, and 2.7-fold in subjects with mild (Creatinine Clearance (CrCL) 50-80 ml/min/1.73 m2), moderate (CrCL 30-<50 ml/min/1.73 m2), and severe (CrCL <30 ml/min/1.73 m2) renal impairment, respectively, compared to subjects with normal renal function (CrCL >80 ml/min/1.73 m2), and AUCs for cilastatin increased 1.6-fold, 2.0-fold, and 6.2-fold in subjects with mild, moderate, and severe renal impairment, respectively, compared to subjects with normal renal function.
• Rødlig opsvulmet tunge, forstørrelse af tungens struktur, der giver et behåret udseende, halsbrand, 
• Red swollen tongue, overgrowth of the normal projections on the tongue giving it a hairy appearance,
• Svær overfølsomhed (f.eks. anafylaktisk reaktion, svær hudreaktion) over for andre beta-lactam antibiotika (f.eks. penicilliner eller cefalosporiner). 
• Severe hypersensitivity (e.g. anaphylactic reaction, severe skin reaction) to any other type of beta lactam antibacterial agent (e.g. penicillins or cephalosporins).
SÅDAN SKAL DE BRUGE TIENAM 
HOW TO USE TIENAM
Den proportionale dosis til patienter <70 kg beregnes ved at dividere patientens aktuelle legemsvægt (i kg) 
The proportionate dose for patients <70 kg would be calculated by dividing the patient's actual body weight (in kg) by 70 kg multiplied by the respective dose recommended in Table 1.
Pædiatrisk population ≥1 år Den anbefalede dosis til pædiatriske patienter ≥1 år er 15/15 eller 25/25 mg/kg/dosis indgivet hver 6. time. 
For paediatric patients ≥1 year of age, the recommended dose is 15/15 or 25/25 mg/kg/dose administered every 6 hours.
• Betændelsestilstand i tarmen med blodig diaré (hæmoragisk colitis) 
• Inflammation of intestine with bloody diarrhoea (haemorrhagic colitis)
Det bruges hos voksne og børn i alderen 1 år og derover til at dræbe et bredt spektrum af bakterier (mikroorganismer), der forårsager infektioner forskellige steder i kroppen. 
It kills a wide range of bacteria (germs) that cause infections in various parts of the body in adults and children one year of age and above.
Ældre Dosisjustering er ikke nødvendig hos ældre patienter med normal nyrefunktion (se pkt. 
Elderly population No dose adjustment is required for the elderly patients with normal renal function (see section 5.2).